Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1993 1
1995 1
1997 1
1998 1
2000 2
2002 1
2003 1
2004 4
2005 3
2006 1
2007 3
2008 4
2009 10
2010 19
2011 15
2012 20
2013 14
2014 18
2015 19
2016 23
2017 15
2018 16
2019 32
2020 24
2021 24
2022 24
2023 17
2024 10
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

284 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Motzer RJ, et al. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Cohen EEW, et al. Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Lancet. 2019. PMID: 30509740 Clinical Trial.
Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
Bossi P, Chan AT, Licitra L, Trama A, Orlandi E, Hui EP, Halámková J, Mattheis S, Baujat B, Hardillo J, Smeele L, van Herpen C, Castro A, Machiels JP; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org; EURACAN. Bossi P, et al. Among authors: van herpen c. Ann Oncol. 2021 Apr;32(4):452-465. doi: 10.1016/j.annonc.2020.12.007. Epub 2020 Dec 25. Ann Oncol. 2021. PMID: 33358989 Free article. No abstract available.
Pan-cancer whole-genome analyses of metastatic solid tumours.
Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, Duyvesteyn K, Haidari S, van Hoeck A, Onstenk W, Roepman P, Voda M, Bloemendal HJ, Tjan-Heijnen VCG, van Herpen CML, Labots M, Witteveen PO, Smit EF, Sleijfer S, Voest EE, Cuppen E. Priestley P, et al. Among authors: van herpen cml. Nature. 2019 Nov;575(7781):210-216. doi: 10.1038/s41586-019-1689-y. Epub 2019 Oct 23. Nature. 2019. PMID: 31645765 Free PMC article.
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Vermorken JB, et al. Among authors: van herpen c. N Engl J Med. 2007 Oct 25;357(17):1695-704. doi: 10.1056/NEJMoa071028. N Engl J Med. 2007. PMID: 17960012 Free article. Clinical Trial.
Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up.
van Herpen C, Vander Poorten V, Skalova A, Terhaard C, Maroldi R, van Engen A, Baujat B, Locati LD, Jensen AD, Smeele L, Hardillo J, Martineau VC, Trama A, Kinloch E, Even C, Machiels JP; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. van Herpen C, et al. ESMO Open. 2022 Dec;7(6):100602. doi: 10.1016/j.esmoop.2022.100602. Epub 2022 Nov 2. ESMO Open. 2022. PMID: 36567082 Free PMC article.
Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis.
Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, Zackrisson B, Szutkowski Z, Suwiński R, Poulsen M, O'Sullivan B, Corvò R, Laskar SG, Fallai C, Yamazaki H, Dobrowsky W, Cho KH, Beadle B, Langendijk JA, Viegas CMP, Hay J, Lotayef M, Parmar MKB, Aupérin A, van Herpen C, Maingon P, Trotti AM, Grau C, Pignon JP, Blanchard P; MARCH Collaborative Group. Lacas B, et al. Among authors: van herpen c. Lancet Oncol. 2017 Sep;18(9):1221-1237. doi: 10.1016/S1470-2045(17)30458-8. Epub 2017 Jul 27. Lancet Oncol. 2017. PMID: 28757375 Free PMC article.
Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.
Resteghini C, Baujat B, Bossi P, Franchi A, de Gabory L, Halamkova J, Haubner F, Hardillo JAU, Hermsen MA, Iacovelli NA, Maroldi R, Mattheis S, Moya-Plana A, Nicolai P, Orlandi E, Thariat J, Trama A, van den Brekel MWM, van Herpen CML, Verillaud B, Kinloch E, Licitra L, Even C; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Resteghini C, et al. Among authors: van herpen cml. ESMO Open. 2025 Feb;10(2):104121. doi: 10.1016/j.esmoop.2024.104121. Epub 2025 Feb 6. ESMO Open. 2025. PMID: 39986703 Free PMC article.
284 results